Proteins

Screening Libraries

Product Data Sheet

APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2

Pancreatic Polypeptide, human

4181.71

Cat. No.: HY-P0199 CAS No.: 75976-10-2

Molecular Formula: $\mathsf{C_{_{185}}H_{_{287}}N_{_{53}}O_{_{54}}S_{_{2}}}$

Molecular Weight: Sequence:

Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Al $a\hbox{-}Ala\hbox{-}Asp\hbox{-}Leu\hbox{-}Arg\hbox{-}Arg\hbox{-}Tyr\hbox{-}Ile\hbox{-}Asn\hbox{-}Met\hbox{-}Leu\hbox{-}Thr\hbox{-}Arg\hbox{-}Pro\hbox{-}Arg\hbox{-}Tyr\hbox{-}NH2$

APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 Sequence Shortening:

Target: Neuropeptide Y Receptor

Pathway: GPCR/G Protein; Neuronal Signaling Storage: Sealed storage, away from moisture

> Powder -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In	V	it	ro
	v		

DMSO: 25 mg/mL (5.98 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	0.2391 mL	1.1957 mL	2.3914 mL
	5 mM	0.0478 mL	0.2391 mL	0.4783 mL
	10 mM			

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (0.60 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (0.60 mM); Clear solution

BIOLOGICAL ACTIVITY

Description Pancreatic Polypeptide, human is a C-terminally amidated 36 amino acid peptide, which acts as a neuropeptide Y (NPY) Y4/

Y5 receptor agonist.

IC₅₀ & Target Neuropeptide Y (NPY) Y4/Y5 receptor^[1]

In Vitro Human pancreatic polypeptide (hPP) is one such peptide, being released postprandially from F cells of the pancreatic islets

Page 1 of 2

^{*} In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

depending on caloric load, food consumption and circadian rhythm. It is a C-terminally amidated 36 amino acid peptide with a characteristic hairpin-like pancreatic polypeptide (PP)-fold and acts at the Y4 receptor to induce satiety and delay gastric emptying and motility^[1]. Addition of the human pancreatic polypeptide (hPP) (10 nM-1 μ M) results in a significant, dose-dependent reduction in both basal and stimulated release. Human pancreatic polypeptide (hPP) can also inhibit basal and stimulated NPY release with a pharmacological profile suggesting a role for Y4 presynaptic receptors^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Thieme V, et al. High molecular weight PEGylation of human pancreatic polypeptide at position 22 improvesstability and reduces food intake in mice. Br J Pharmacol. 2016 Nov;173(22):3208-3221.

[2]. King PJ, et al. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J Neurochem. 1999 Aug;73(2):641-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com